title: Comparisons of curative and side effects of chemoradiotherapy among Xinjiang Han, Uigur and Kazakh esophageal carcinoma patients.
abstract: OBJECTIVE
  This study aimed to explore the differences in the curative and side effects of chemoradiotherapy on esophageal cancer (EC) among Xinjiang Han, Uigur and Kazakh patients.
  
  
  METHODS
  170 patients with IIA stage-IV of esophageal squamous cell carcinoma were analyzed retrospectively. Based on different nationalities, they were divided into the Han, Uigur and Kazakh groups. The 1-, 2- and 3-year survival rates, incidence of the side effects (including hematological toxicities, radioactive esophagitis and percutaneous reactions) and application of antibiotics and harmonics were compared among the groups. There was no significant difference in the short-term curative effects among the Han, Uigur and Kazakh groups. The 1- 2- and 3-year survival rates of the three groups were 84%, 40%, 26%; 78%, 27%, 18%; and 60%, 21%, 12% (x2=14.497, P<0.05). The incidence rate of hamatological toxicity ≥ Grade 2 in the Kazakh group was significantly lower than that in the Han or Uigur group.
  
  
  RESULTS
  The incidence rates of radioactive esophagitis and percutaneous reactions Grade 2 in the Han group were significantly higher than those in the Uigur or Kazakh group. There was no significant difference in the types of applied antibiotics among the groups, but there were significant differences in the days of antibiotic application and proportion of patients receiving harmonics between the Hans and either of other groups.
  
  
  CONCLUSIONS
  Chemoradiotherapy shows a better effect in the long-term survival rate among Han EC patients compared with Uigur or Kazakh EC patients. Uigur and Kazakh patients show a better tolerance to the side effects of chemoradiotherapy compared with Hans.
authors.affiliation: Cancer Center of The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, Urumqi, China. lizhangcn@126.com
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Ma
authors.forename: Jian-Qing
authors.initials: JQ
authors.lastname: Zhang
authors.forename: Mei
authors.initials: M
authors.lastname: Yang
authors.forename: Tu-Er
authors.initials: TE
authors.lastname: Xun
authors.forename: Ai
authors.initials: A
authors.lastname: Li
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects*; D004938:Esophageal Neoplasms / Q000401:mortality* / Q000628:therapy*; D004941:Esophagitis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology; D015996:Survival Rate